0718 GMT - Novartis's trial results for its ianalumab drug candidate in autoimmune disorder Sjoegren's disease suggests the company's next pipeline in a pill--or a drug marketed for multiple indications--could be under way, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said it is testing the drug in other diseases. Ianalumab worked in two late-stage trials and this could pave the way for a systematic treatment for a disease for which there are only limited symptomatic treatments available at the moment, the analyst says. This could increase the diagnosis rate, as the scientific literature estimates 50% of patients are undiagnosed, the analyst says. Vontobel estimates peak sales for the drug at $1 billion. Novartis shares rise 2.3%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
August 11, 2025 03:18 ET (07:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.